CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash flows from operating activities:
Net income (loss) after equity in losses from unconsolidated affiliates	$ 1,304	$ (11,913)
Adjustments to reconcile net income (loss) to cash provided by (used in) operating activities:
Depreciation and amortization	6,680	4,704
Non-cash impact of operating leases	1,050	840
Deferred income tax benefit	(3,294)	(1,776)
Stock-based compensation	9,457	2,797
Equity in losses of unconsolidated affiliates	(529)	217
Accretion of discounts and issuance costs	35	3,049
Other losses	768	65
Changes in operating assets and liabilities (net of the effect of acquisitions):
Accounts receivable	3,046	(1,268)
Inventories	(4,080)	(4,094)
Other assets	(4,404)	(56)
Accounts payable	(334)	(2,732)
Other liabilities	(3,603)	(2,928)
Net cash provided by (used in) operating activities	7,154	(13,095)
Cash flows from investing activities:
Promissory note receivable issuance	(9,000)	0
Purchases of property and equipment	(546)	(316)
Proceeds from disposition of property and equipment	41	0
Net cash used in investing activities	(13,387)	(119,926)
Cash flows from financing activities:
Payment of stock issuance costs	(314)	(214)
Preferred stock proceeds	0	122,000
Proceeds from issuance of common stock	167,198	1,514
Repurchase of common stock	(932)	(610)
Repayments of other debt	(653)	(109)
Borrowings on other debts	0	410
Net cash provided by financing activities	165,299	122,991
Foreign exchange effect on cash and cash equivalents	(247)	189
Net increase (decrease) in cash and cash equivalents	158,819	(9,841)
Cash and cash equivalents, beginning of period	86,334	89,030
Cash and cash equivalents, end of period	245,153	79,189
Supplemental disclosure of cash flow information:
Non-cash transfers of equipment between inventory and property and equipment, net	2,562	1,560
Non-cash conversion of preferred stock to common stock	0	122,000
Consideration payable for scil acquisition	0	537
Contingent consideration for acquisition	1,700	0
Indemnity holdback for acquisition	370	0
CVM
Cash flows from investing activities:
Acquisition of CVM	0	(14,420)
Lacuna Diagnostics, Inc.
Cash flows from investing activities:
Acquisition of CVM	(3,882)	0
Scil Animal Care Company
Cash flows from investing activities:
Acquisition of CVM	$ 0	$ (105,190)